Daiichi Sankyo

Sketch of lungs
Biotech

Merck, Daiichi ADC hits goal in phase 3 lung cancer study

The trial hit its primary endpoint, boosting plans to take a second shot at FDA approval, but two more people died and the OS data are immature.
Nick Paul Taylor Sep 17, 2024 7:13am
lung cancer

AstraZeneca, Daiichi unpack Dato-DXd's overall survival fail

Sep 10, 2024 6:00am
Lung model

Merck, Daiichi repeat early success in small cell lung cancer

Sep 9, 2024 10:27am
AZ

AZ outlines AI-enabled TROP2 biomarker strategy for Daiichi ADC

Sep 8, 2024 12:22pm
Combine

Daiichi pays Merck $170M to form lung cancer T-cell engager pact

Aug 6, 2024 8:17am
AstraZeneca

AstraZeneca-Daiichi's Dato-DXd didn't prove OS benefit in ph. 3

May 28, 2024 7:06am